Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-06-26
2009-08-04
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C424S141100, C424S155100, C424S178100, C435S007230, C435S069600, C435S070210, C530S388100, C530S388800, C530S391300
Reexamination Certificate
active
07569673
ABSTRACT:
The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5472693 (1995-12-01), Gourlie et al.
patent: 5482040 (1996-01-01), Martin, Jr.
patent: 5512443 (1996-04-01), Schlom et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5976531 (1999-11-01), Mezes et al.
patent: 5976845 (1999-11-01), Mezes et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6495137 (2002-12-01), Mezes et al.
patent: 7081518 (2006-07-01), Pastan et al.
patent: 2131355 (2001-04-01), None
patent: 2068593 (2003-07-01), None
patent: 0239400 (1987-09-01), None
patent: 0365997 (1990-05-01), None
patent: WO 89/00692 (1989-01-01), None
patent: WO 89/01783 (1989-05-01), None
patent: WO 90/04410 (1990-05-01), None
patent: WO 91/00295 (1991-01-01), None
patent: WO 93/12231 (1993-06-01), None
patent: WO 96/13594 (1996-05-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO 98/18809 (1998-05-01), None
patent: WO 99/43816 (1999-02-01), None
patent: WO 00/26394 (2000-05-01), None
Iwahashi et al. Molecular Immunology, 1999. 36:1079-1091.
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982.
Colman. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Abergel et al., “Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab',”Proteins: Structure, Function, and Genetics17:438-443, 1993.
Colcher et al., “Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies,”Cancer Research48:4597-4603, Aug. 15, 1988.
De Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,”J. Immunol. 169:3076-3084, 2002.
De Pascalis et al., “In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants,”Clin. Can. Res. 9:5521-5531, 2003.
Divgi et al., “Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen,”Nucl. Med. Biol. 21(1):9-15, 1994.
Gonzales et al., “Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues,”Mol. Immunol. 40:337-349, 2003.
Hakimi et al., “Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys,”J. Immunol. 147:1352-1359, 1991.
Hand et al., “Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma,”Cancer Supplement73(3):1105-1113, Feb. 1, 1994.
Iwahashi et al., “CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity,”Mol. Immunol. 36:1079-1091:1999.
Johnson et al., “Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3,”Cancer Research46:850-857, Feb. 1986.
Jones et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,”Nature321:522-525, May 29, 1986.
Kashmiri et al., “Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49,”Hybridoma14(5):461-473, 1995.
Kashmiri et al., “Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49,”Crit. Rev. Oncol. Hematol. 38:3-16, 2001.
Kashmiri et al., Chapter 21 inMethods in Molecular Biology, vol. 248:Antibody Engineering: Methods and Protocols, p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003.
Mulligan et al., “Phase I Study of Intravenous177Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma,”Clinical Cancer Research1:1447-1454, Dec. 1995.
Muraro et al., “Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen,”Cancer Research48:4588-4596, Aug. 15, 1988.
Padlan, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties,”Molecular Immunology28(4/5):489-498, 1991.
Padlan, “Anatomy of the antibody molecule,”Mol. Immunol. 31:169-217, 1994.
Padlan et al., “Identification of Specificity-determining Residues in Antibodies,”The FASEB Journal9:133-139, Jan. 1995.
Paul,Fundamental Immunology, Raven Press, NY, Ch. 8, p. 242, 1993.
Reichman et al., “Reshaping human antibodies for therapy,”Nature(London) 332:323-327, 1988.
Rixon et al., “Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies,”The Journal of Immunology151(11):6559-6568, Dec. 1, 1993.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”Proc Natl Acad Sci U S A. March; 79(6): 1979-1983, 1982.
Saldanha et al., “A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells,”Mol. Immunol. 36:709-719, 1999.
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site,”J. Mol. Biol. 263:551-567, 1996.
Sha et al., “A heavy-chain grafted antibody that recognizes the tumor-associated TAG72 antigen,”Cancer Biother. 9(4):341-349, 1994.
Sharkey et al., “Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies,”Cancer Res. 55:5935s-5945s, 1995.
Slavin-Chiorini et al., “Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins,”Cancer Res. 55(23 Suppl.):5957s-5967s, 1995.
Slavin-Chiorini et al., “A CDR-grafted (humanized) domain-deleted antitumor antibody,”Cancer Biother. Radiopharm. 12:305-316, 1997.
Tamura et al., “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,”J. Immunol. 164:1432-1441, 2000.
Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,”J. Mol. Biol.294:151-162, 1999.
Xiang et al., “The tyrosine residue at position 97 in the VH CDR3 region of a mouse/human chimeric anti-colorectal carcinoma antibody contributes hydrogen bonding to the
Kashmiri Syed V. S.
Padlan Eduardo A.
Schlom Jeffrey
Blanchard David J.
Klarquist Sparkman LLP.
The United States of America as represented by the Department of
LandOfFree
Humanized anti-tag 72 cc49 for diagnosis and therapy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-tag 72 cc49 for diagnosis and therapy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-tag 72 cc49 for diagnosis and therapy of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075748